Ignite Creation Date:
2024-05-06 @ 1:03 AM
Last Modification Date:
2024-10-26 @ 10:58 AM
Study NCT ID:
NCT01711671
Status:
COMPLETED
Last Update Posted:
2017-03-13
First Post:
2012-10-18
Brief Title:
A Study of DKN-01 and LenalidomideDexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor:
Leap Therapeutics Inc
Organization:
Leap Therapeutics Inc
Study Overview
Official Title:
A Pilot Study of DKN-01 and Lenalidomide RevlimidDexamethasone Versus LenalidomideDexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to evaluate the safety efficacy and bone changes with combination therapy of intravenous IV infused DKN-01 and lenalidomidedexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma MM patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DKN-01 | None | None | None |
| LY2812176 | None | None | None |